### Key Figures

<table>
<thead>
<tr>
<th>H1 2021</th>
<th>Δ in %</th>
<th>H1 2020¹</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue (Δ in const. fx)</td>
<td>1,629.2</td>
<td>+60.1</td>
<td>1,056.8</td>
<td>2,335.7</td>
</tr>
<tr>
<td>Order intake (Δ in const. fx)</td>
<td>2,178.8</td>
<td>+82.4</td>
<td>1,244.8</td>
<td>2,836.3</td>
</tr>
<tr>
<td>Underlying EBITDA²</td>
<td>555.3</td>
<td>+89.2</td>
<td>293.5</td>
<td>692.2</td>
</tr>
<tr>
<td>Underlying EBITDA² margin in %</td>
<td>34.1</td>
<td>27.8</td>
<td>29.6</td>
<td>27.1</td>
</tr>
<tr>
<td>Relevant net profit continuing operations³</td>
<td>259.4</td>
<td>+108.7</td>
<td>124.3</td>
<td>299.3</td>
</tr>
<tr>
<td>Underlying EPS per ordinary share³ in €</td>
<td>3.79</td>
<td>+108.9</td>
<td>1.81</td>
<td>4.37</td>
</tr>
<tr>
<td>Underlying EPS per preference share³ in €</td>
<td>3.80</td>
<td>+108.3</td>
<td>1.82</td>
<td>4.38</td>
</tr>
<tr>
<td>Equity ratio in %</td>
<td>31.3</td>
<td>30.0</td>
<td>29.9</td>
<td>38.1</td>
</tr>
<tr>
<td>Net debt to underlying EBITDA⁴</td>
<td>1.8</td>
<td>2.8</td>
<td>2.6</td>
<td>2.0</td>
</tr>
</tbody>
</table>

¹ Figures for the comparable period have been restated due to finalization of the purchase price allocations for the acquisitions of 2020.
² Underlying = adjusted for extraordinary items.
³ After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and the normalized tax rate.
⁴ EBITDA including the underlying pro forma amount contributed by acquisitions for this period.

### Sales Revenue by Division 2020

- **Bioprocess Solutions**: ~74% (~€2.34bn)
- **Lab Products & Services**: ~26%

### Sales Revenue by Region 2020

- **Americas**: 35%
- **EMEA**: 40%
- **Asia | Pacific**: 25%

EMEA = Europe | Middle East | Africa

### Earnings per Share¹ in €

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares (SRT)</td>
<td>1.94</td>
<td>2.11</td>
<td>2.57</td>
<td>3.07</td>
<td>4.38</td>
</tr>
<tr>
<td>Preference shares (SRT3)</td>
<td>1.93</td>
<td>2.10</td>
<td>2.56</td>
<td>3.06</td>
<td>4.37</td>
</tr>
</tbody>
</table>

¹ After non-controlling interest, adjusted for extraordinary items as well as non-cash amortization, and based on a normalized financial result and the normalized tax rate.

### Investment Highlights

1. Clear focus on the attractive biopharma sector
2. Long-term growth drivers and significant market entrance barriers
3. Market leading position in key technologies and recognized brand
4. High share of recurring revenue as well as diversified earnings base
5. Proven track record with alliances and acquisitions; strong presence in growth regions

### 2021 Guidance¹

<table>
<thead>
<tr>
<th></th>
<th>Sales Revenue Growth</th>
<th>EBITDA-Margin²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius Group</td>
<td>~45%</td>
<td>~34%</td>
</tr>
<tr>
<td>Bioprocess Solutions</td>
<td>~50%</td>
<td>~36%</td>
</tr>
<tr>
<td>Lab Products &amp; Services</td>
<td>~30%</td>
<td>~26%</td>
</tr>
<tr>
<td>Capex Ratio</td>
<td>~12%</td>
<td></td>
</tr>
</tbody>
</table>

¹ In constant currencies.
² Underlying = excluding extraordinary items.
Division Strategy

Bioprocess Solutions
- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers' production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and cell cultivation
- One of the widest portfolios in the industry; clear focus on single-use technologies such as filters, bags and cell culture media
- Continuous expansion through complementary acquisitions and targeted alliances

Lab Products & Services
- Premium provider of laboratory instruments, consumables and services for sample preparation and bioanalytic
- Leading international positions in laboratory balances, pipettes and lab consumables
- Outstanding brand reputation, strong product range and global services as the basis for further expansion of market share
- Extension of portfolio with complementary laboratory products through acquisitions and alliances

Facts about Preference Shares

Ticker symbol: SRT3
Ticker symbol Bloomberg: SRT3 GY
Ticker symbol Reuters: SATG.pe.DE
WKN | ISIN: 716 563 | DE0007165631

Facts about Ordinary Shares

Ticker symbol: SRT
Ticker symbol Bloomberg: SRT GY
Ticker symbol Reuters: SATG
WKN | ISIN: 716 560 | DE0007165607

Shareholder Structure: Ordinary Shares

December 31, 2020
- Administered by an executor: ~55%
- Bio-Rad Laboratories Inc.: ~38%
- Free float: ~7%

Shareholder Structure: Preference Shares

December 31, 2020
- Bio-Rad Laboratories Inc.: ~28%
- Free float: ~72%

Financial Calendar

October 20, 2021
Publication of third-quarter figures for 2021

Disclaimer

This fact sheet contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.